Focus: Bioserenity is a French biotech founded in 2014 specializing in epilepsy diagnosis through innovative sensor and diagnostic technologies. The company operates as a pre-revenue or early-stage medical device/diagnostic innovator with a focused neurology and neurological monitoring platform.
Profile data last refreshed 22m ago · AI intelligence enriched 3w ago
Hot — 42 jobs added in 30d
Net +37 (42 new, 5 removed). Aggressive expansion phase.
Bioserenity represents a high-risk, high-potential early-stage diagnostic play best suited for career-builders seeking ground-floor operational or commercial experience in neurology, but requiring comfort with pre-clinical stage execution and financial opacity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bioserenity
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bioserenity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo